Landos Biopharma, Inc (LABP)

Etorro trading 970x250

About Landos Biopharma, Inc

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn’s disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia. Address: 1800 Kraft Drive, Blacksburg, VA, United States, 24060

Landos Biopharma, Inc News and around…

Latest news about Landos Biopharma, Inc (LABP) common stock and company :

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
20 Oct, 2021 FinancialContent

Upgrades For Iridium Communications Inc (NASDAQ:IRDM), BWS Financial upgraded the previous rating of Neutral to Buy. Iridium ...

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
19 Oct, 2021 FinancialContent

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:INDP) from Hold to Buy. Indaptus Therapeutics ...

10 Best Biotech Stocks to Buy According to Joseph Edelman’s Perceptive Advisors
15 Oct, 2021 Yahoo! Finance

In this article, we will discuss the 10 best biotech stocks to buy according to Joseph Edelman’s Perceptive Advisors. If you want to skip our detailed analysis of Edelman’s history, investment philosophy, and hedge fund performance, go directly to the 5 Best Biotech Stocks to Buy According to Joseph Edelman’s Perceptive Advisors. Joseph Edelman, the […]

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
11 Oct, 2021 Yahoo! Finance

Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for LABP-104, a novel

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor’s Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism
06 Oct, 2021 Yahoo! Finance

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced the publication of a peer-reviewed article titled “First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of the LANCL2 pathway in psoriasis” in Scientific Reports.

Landos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual)
27 Sep, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
23 Sep, 2021 FinancialContent

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:WMG) from Equal-Weight to Overweight. ...

Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn’s Disease with the Icahn School of Medicine at Mount Sinai
20 Sep, 2021 FinancialContent
Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021
15 Sep, 2021 FinancialContent
Landos Biopharma to Participate in Two Upcoming Investor Conferences in September
01 Sep, 2021 FinancialContent
Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine
26 Aug, 2021 FinancialContent
Here's What Landos Biopharma, Inc.'s (NASDAQ:LABP) Shareholder Ownership Structure Looks Like
19 Aug, 2021 Yahoo! Finance

Every investor in Landos Biopharma, Inc. ( NASDAQ:LABP ) should be aware of the most powerful shareholder groups...

Landos Biopharma to Participate in Upcoming Investor Events
05 Aug, 2021 FinancialContent
Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates
29 Jul, 2021 FinancialContent
Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021
22 Jul, 2021 FinancialContent
54 Biggest Movers From Yesterday
20 Jul, 2021 FinancialContent

Gainers Aehr Test Systems (NASDAQ: AEHR) shares climbed 87.9% to close at $6.39 on Monday after the company won a $10.8 million ...

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference
14 Jun, 2021 FinancialContent
Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients
14 Jun, 2021 FinancialContent

The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor

Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference
25 May, 2021 FinancialContent
Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
22 May, 2021 FinancialContent

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones.

Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors
19 May, 2021 FinancialContent
Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China
17 May, 2021 FinancialContent

Landos Biopharma Inc(NASDAQ:LABP) andLianBiohaveannounced an exclusive collaboration and license ...

Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates
17 May, 2021 FinancialContent
LianBio Acquires Two IBD Candidates from Landos in $218 Million Agreement
17 May, 2021 FinancialContent

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones. The two assets are novel, oral, gut-restricted agonists, both of which are in trials for ulcerative colitis and Crohn's disease. LianBio was formed by Perceptive Advisors, a US healthcare investor, and Landos was backed by Xontology, which partnered with Perceptive to form  two funds that invest in biopharma startups. More details... Stock Symbol: (NSDQ: LABP) Share this with colleagues:

Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets
17 May, 2021 FinancialContent
Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies
12 May, 2021 FinancialContent

Xontogeny LLC, a Boston-based accelerator, unveiled five of its latest portfolio companies.

Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease
06 May, 2021 FinancialContent
Is Landos Biopharma (NASDAQ:LABP) In A Good Position To Invest In Growth?
04 May, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis
29 Apr, 2021 FinancialContent
58 Biggest Movers From Yesterday
27 Apr, 2021 FinancialContent

Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) shares jumped 104.2% to close at $8.70 on Monday after the company ...

Landos Biopharma, Inc (LABP) is a NASDAQ Common Stock listed in , ,

970x250